INTERACTION OF AZA ANALOGS OF CHLORPROMAZINE WITH THE DOPAMINE-D2 RECEPTOR

被引:5
|
作者
FAROOQUI, T [1 ]
MARKOVICH, K [1 ]
WALLACE, L [1 ]
MILLER, D [1 ]
URETSKY, N [1 ]
机构
[1] OHIO STATE UNIV,COLL PHARM,DIV PHARMACOL & MED,COLUMBUS,OH 43210
来源
GENERAL PHARMACOLOGY | 1993年 / 24卷 / 01期
关键词
D O I
10.1016/0306-3623(93)90026-T
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Permanently charged AZA analogs of chlorpromazine inhibited the binding of [H-3]spiperone and antagonized the apomorphine-induced inhibition of the potassium evoked release of [H-3]acetylcholine. 2. The AZA analogs were more potent in binding affinity and antagonist activity than the trimethylammonium analog of chlorpromazine but less potent than chlorpromazine. 3. These results suggest that it is possible to enhance the binding of the permanently charged trimethylammonium analog of chlorpromazine by the addition of a functional group near the quaternary nitrogen which is capable of forming a hydrogen bond with the D2 dopamine receptor. 4. However, it appears that for optimal binding, as achieved with chlorpromazine, the hydrogen-bonding proton should be on the charged nitrogen.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 50 条
  • [21] THE DOPAMINE-D2 RECEPTOR LOCUS AS A MODIFYING GENE IN NEUROPSYCHIATRIC DISORDERS
    COMINGS, DE
    COMINGS, BG
    MUHLEMAN, D
    DIETZ, G
    SHAHBAHRAMI, B
    TAST, D
    KNELL, E
    KOCSIS, P
    BAUMGARTEN, R
    KOVACS, BW
    LEVY, DL
    SMITH, M
    BORISON, RL
    EVANS, DD
    KLEIN, DN
    MACMURRAY, J
    TOSK, JM
    SVERD, J
    GYSIN, R
    FLANAGAN, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (13): : 1793 - 1800
  • [22] EFFECTS OF DOPAMINE-D1 AND DOPAMINE-D2 RECEPTOR ANTAGONISTS ON ORAL ACTIVITY IN RATS
    LEVIN, ED
    SEE, RE
    SOUTH, D
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1989, 34 (01) : 43 - 48
  • [23] SITE-DIRECTED MUTAGENESIS OF THE HUMAN DOPAMINE-D2 RECEPTOR
    MANSOUR, A
    MENG, F
    MEADORWOODRUFF, JH
    TAYLOR, LP
    CIVELLI, O
    AKIL, H
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 227 (02): : 205 - 214
  • [24] THE INTERACTION OF AMMONIUM, SULFONIUM, AND SULFIDE ANALOGS OF METOCLOPRAMIDE WITH THE DOPAMINE-D(2) RECEPTOR
    HARROLD, MW
    SRIBURI, A
    MATSUMOTO, K
    MILLER, DD
    FAROOQUI, T
    URETSKY, N
    JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (21) : 3166 - 3170
  • [25] NMDA RECEPTOR ANTAGONISTS INHIBIT CATALEPSY INDUCED BY EITHER DOPAMINE-D1 OR DOPAMINE-D2 RECEPTOR ANTAGONISTS
    MOORE, NA
    BLACKMAN, A
    AWERE, S
    LEANDER, JD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 237 (01) : 1 - 7
  • [26] FUNCTIONAL INTERACTION BETWEEN DOPAMINE-D1 AND DOPAMINE-D2 RECEPTORS IN RAT JAW MOVEMENTS
    KOSHIKAWA, N
    DEBELTRAN, KK
    TOMIYAMA, K
    KOBAYASHI, M
    COOLS, AR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 201 (01) : 47 - 51
  • [27] IRREVERSIBLE INTERACTION OF BETA-HALOALKYLAMINE DERIVATIVES WITH DOPAMINE-D1 AND DOPAMINE-D2 RECEPTORS
    CROSS, AJ
    WADDINGTON, JL
    ROSS, ST
    LIFE SCIENCES, 1983, 32 (24) : 2733 - 2740
  • [28] SEPARATION OF DOPAMINE-D1 AND DOPAMINE-D2 RECEPTORS
    DUMBRILLEROSS, A
    NIZNIK, H
    SEEMAN, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 110 (01) : 151 - 152
  • [29] DOPAMINE-D2 RECEPTOR AGENTS, BUT NOT DOPAMINE-D1, MODIFY BRAIN GLUCOSE-METABOLISM
    PALACIOS, JM
    WIEDERHOLD, KH
    BRAIN RESEARCH, 1985, 327 (1-2) : 390 - 394
  • [30] DOPAMINE-D2 RECEPTOR-BINDING SITES FOR AGONISTS - A TETRAHEDRAL MODEL
    SEEMAN, P
    WATANABE, M
    GRIGORIADIS, D
    TEDESCO, JL
    GEORGE, SR
    SVENSSON, U
    NILSSON, JLG
    NEUMEYER, JL
    MOLECULAR PHARMACOLOGY, 1985, 28 (05) : 391 - 399